EFFECT OF 14-MEMBERED RING MACROLIDE THERAPY ON CHRONIC RESPIRATORY-TRACT INFECTIONS AND POLYMORPHONUCLEAR LEUKOCYTE ACTIVITY

被引：48

作者：

SHIRAI, T

SATO, A

CHIDA, K

机构：

[1] Second Division, Department of Internal Medicine, Hamamatsu University, School of Medicine, Hamamatsu

来源：

INTERNAL MEDICINE | 1995年 / 34卷 / 06期

关键词：

DIFFUSE PANBRONCHIOLITIS; BRONCHIECTASIS; ERYTHROMYCIN; ROXITHROMYCIN; CLARITHROMYCIN;

D O I：

10.2169/internalmedicine.34.469

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We studied the efficacy of the long-term administration of 14-membered ring macrolides in treating patients with diffuse panbronchiolitis (DPB) (34 patients) and bronchiectasis (BE) (40 patients). Oral administration of erythromycin (400 or 600 mg), roxithromycin (150 or 300 mg) or clarithromycin (200 or 400 mg) given daily for at least 2 months, was evaluated. The efficacy of erythromycin, roxithromycin, and clarithromycin in DPB was 19/24 (79%), 6/7 (86%), and 2/3 (67%), respectively. Efficacy of these agents in BE exceeded 50%. We determined the effect of these macrolides on the activity of polymorphonuclear leukocytes (PMNs) obtained from healthy volunteers. There were no significant differences between the effects of these 14-membered ring macrolides and josamycin, a 16-membered ring macrolide which was previously found to be ineffective in treating DPB. Thus, the effectiveness of the 14-membered ring macrolides in treating DPB appears to depend on mechanism(s) other than alterations in PMN activity.

引用

页码：469 / 474

页数：6

共 29 条

[1]

Homma H., Yamanaka A., Tanimoto S., Et al., Diffuse panbronchiolitis: a disease of the transitional zone of the lung, Chest, 83, (1983)

[2]

Fraser R.G., Pare J.A.P., Pare P.D., Fraser R.S., Genereux G.P., Diffuse Panbronchiolitis, Diagnosis of Diseases of the Chest, (1990)

[3]

Kudoh S., Uetake T., Hagiwara K., Et al., Clinical effect of low-dose longterm erythromycin chemotherapy on diffuse panbronchiolitis, Jpn J Thorac Dis, 25, (1987)

[4]

Yamamoto M., Kondo A., Tamura M., Izumi T., Ina Y., Noda M., Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis, Jpn J Thorac Dis, 28, (1990)

[5]

Nagai H., Shishido H., Yoneda R., Yamaguchi E., Tamura A., Kurashima A., Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis, Respiration, 58, (1991)

[6]

Yamamoto M., Kudoh S., Noda M., Et al., Efficacy of erythromycin on diffuse panbronchiolitis

[7]

randamized placebo-controlled double-blind study, Am Rev Respir Dis (manuscript in communication)

[8]

Ichikawa Y., Koga H., Tanaka M., Nakamura M., Tokunaga N., Kaji M., Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis, Chest, 98, (1990)

[9]

Cantin A.M., North S.L., Fells G.A., Hubbard R.C., Crystal R.G., Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis, J Clin Invest, 79, (1987)

[10]

Kindt G.C., Weiland J.E., Davis W.B., Gadek J.E., Dorinsky P.M., Bronchiolitis in adults: a reversible cause of airway obstruction associated with airway neutrophils and neutrophil products, Am Rev Respir Dis, 140, (1989)

← 1 2 3 →